BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $434,751 | -27.7% | 11,520 | -12.7% | 0.01% | -27.8% |
| Q2 2023 | $601,385 | -0.5% | 13,200 | -11.4% | 0.02% | -10.0% |
| Q1 2023 | $604,143 | -25.3% | 14,895 | -6.1% | 0.02% | -28.6% |
| Q4 2022 | $808,324 | -34.7% | 15,859 | -31.0% | 0.03% | -44.0% |
| Q3 2022 | $1,238,000 | -23.9% | 22,997 | -9.2% | 0.05% | -24.2% |
| Q2 2022 | $1,626,000 | -20.5% | 25,317 | -4.0% | 0.07% | -24.1% |
| Q1 2022 | $2,045,000 | -11.1% | 26,378 | -1.5% | 0.09% | -10.3% |
| Q4 2021 | $2,300,000 | +6.5% | 26,791 | -0.3% | 0.10% | -2.0% |
| Q3 2021 | $2,160,000 | -3.9% | 26,859 | -3.8% | 0.10% | -5.7% |
| Q2 2021 | $2,247,000 | -6.6% | 27,917 | -2.1% | 0.10% | -12.5% |
| Q1 2021 | $2,406,000 | -16.5% | 28,528 | -20.5% | 0.12% | -16.7% |
| Q4 2020 | $2,881,000 | -2.5% | 35,903 | -2.3% | 0.14% | -16.3% |
| Q3 2020 | $2,955,000 | -7.7% | 36,740 | -1.1% | 0.17% | -16.9% |
| Q2 2020 | $3,200,000 | +3.0% | 37,164 | -2.9% | 0.21% | -18.8% |
| Q1 2020 | $3,108,000 | -10.2% | 38,282 | -7.5% | 0.26% | +2.4% |
| Q4 2019 | $3,460,000 | -3.4% | 41,374 | +1.1% | 0.25% | -12.9% |
| Q3 2019 | $3,581,000 | +5.1% | 40,935 | -1.6% | 0.29% | +3.6% |
| Q2 2019 | $3,407,000 | +3.4% | 41,601 | +2.7% | 0.28% | +1.1% |
| Q1 2019 | $3,294,000 | +27.7% | 40,509 | +3.3% | 0.27% | +3.4% |
| Q4 2018 | $2,580,000 | -3.0% | 39,203 | +13.6% | 0.26% | +13.3% |
| Q3 2018 | $2,661,000 | -12.8% | 34,516 | -16.5% | 0.23% | -21.3% |
| Q2 2018 | $3,052,000 | +15.6% | 41,331 | +1.8% | 0.30% | +11.7% |
| Q1 2018 | $2,641,000 | +2.0% | 40,599 | +1.4% | 0.26% | +2.3% |
| Q4 2017 | $2,589,000 | +6.0% | 40,047 | +2.9% | 0.26% | -3.7% |
| Q3 2017 | $2,442,000 | +4.7% | 38,918 | +1.0% | 0.27% | +1.9% |
| Q2 2017 | $2,332,000 | +17.5% | 38,521 | +0.6% | 0.26% | +9.1% |
| Q1 2017 | $1,985,000 | +52.9% | 38,282 | +30.8% | 0.24% | +42.4% |
| Q4 2016 | $1,298,000 | -2.7% | 29,277 | +4.5% | 0.17% | -8.6% |
| Q3 2016 | $1,334,000 | +8.2% | 28,027 | +2.8% | 0.19% | +1.6% |
| Q2 2016 | $1,233,000 | +4.1% | 27,273 | -5.4% | 0.18% | -3.2% |
| Q1 2016 | $1,184,000 | +18.4% | 28,823 | +10.0% | 0.19% | +26.0% |
| Q4 2015 | $1,000,000 | +72.7% | 26,213 | +48.7% | 0.15% | +47.1% |
| Q3 2015 | $579,000 | -55.1% | 17,631 | -4.4% | 0.10% | -47.2% |
| Q2 2015 | $1,289,000 | +6.4% | 18,438 | +4.2% | 0.19% | +9.7% |
| Q1 2015 | $1,212,000 | -4.9% | 17,689 | +1.7% | 0.18% | -15.8% |
| Q4 2014 | $1,275,000 | +11.5% | 17,396 | +9.2% | 0.21% | +6.1% |
| Q3 2014 | $1,143,000 | +0.4% | 15,932 | +1.1% | 0.20% | +1.5% |
| Q2 2014 | $1,139,000 | -6.8% | 15,757 | -5.5% | 0.19% | -10.2% |
| Q1 2014 | $1,222,000 | +33.0% | 16,678 | +26.2% | 0.22% | +27.1% |
| Q4 2013 | $919,000 | +151.8% | 13,213 | +137.7% | 0.17% | +126.7% |
| Q3 2013 | $365,000 | – | 5,558 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |